Albert Bourla - Dec 17, 2021 Form 4 Insider Report for PFIZER INC (PFE)

Role: Chairman & CEO, Director
Signature: Susan E. Grant, by power of atty., for Albert Bourla
Stock symbol: PFE
Transactions as of: Dec 17, 2021
Transactions value $: $3,289,547
Form type: 4
Date filed: 12/21/2021, 05:03 PM
Previous filing: Dec 16, 2021
Next filing: Jan 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PFE	Common Stock	Options Exercise	$2.19M	+80.1K	+64.9%	$27.34	203K	Dec 17, 2021	Direct	F1
transaction	PFE	Common Stock	Options Exercise	$1.1M	+43K	+21.12%	$25.60	246K	Dec 17, 2021	Direct	F2
holding	PFE	Common Stock						3.88K	Dec 17, 2021	By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-154K	-100%	$0.00^*	0	Dec 17, 2021	Common Stock	154K	$27.34	Direct
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-77.7K	-100%	$0.00^*	0	Dec 17, 2021	Common Stock	77.7K	$25.60	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.
F2	Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.

Content

Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $53.791)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.